AFYX Therapeutics A/S

AFYX is a Biopharmaceutical company with a focus on reformulation and repurposing of pharmaceuticals. REVERSED INNOVATION We find new indications for existing technologies. Through our research, we work relentlessly to improve lives by addressing unmet medical needs. Reversed Innovation is our core value. As a leader in the biopharmaceutical industry, reversed innovation aligns with the broader theme, as we take an existing product or technology and use to address a new or previously overlooked or unconsidered medical problem or condition. WE HAVE MERGED A DECADE OF TECHNOLOGY INPHENA A/S, a company that already has commercial activities in several countries and develops repurposed existing pharmaceutical substances for new indications. LIONHEART, a company focused on the treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication. AFYX THERAPEUTICS A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc; Genmab A/S and Y-mAbs Therapeutics, Inc.)